Alliance Pharma (APH) Share Price, News & Analysis

Company Overview

Alliance Pharma plc operates as a pharmaceutical company in Europe, the Middle East, Africa, the Asia Pacific, China, and the Americas. The company acquires, markets, and distributes consumer healthcare and prescription medicine products. The company also offers medicines, medical devices, food supplements, and cosmetics. It provides its products under the Aloclair, Anbesol, Asthon and Parsons, Forceval, Hydromol, Kelo-cote, Macushield, Vamousse, Nizoral, and Amberen brand names. Alliance Pharma plc was incorporated in 1996 and is headquartered in Chippenham, the United Kingdom.

Key Stats

• Today's Range: 60.30 to 66.20
• 50-Day Range: 44 to 61.50
• 52-Week Range: 24.55 to 66.20
• Volume: 3.39 million shs
• Average Volume: 6.21 million shs
• Market Capitalization: £329.20 million
• P/E Ratio: N/A
• Dividend Yield: 3.29%
• Price Target: GBX 6,250
• Consensus Rating: Hold

Alliance Pharma Stock Analysis - MarketRank™

Alliance Pharma scored higher than 57% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Hold

Consensus Rating

Alliance Pharma has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Alliance Pharma has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Alliance Pharma is -9.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Alliance Pharma is -9.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Growth Ratio

Alliance Pharma has a PEG Ratio of 1.04. PEG Ratios around 1 indicate that a company is correctly valued.

Price to Book Value per Share Ratio

Alliance Pharma has a P/B Ratio of 1.47. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for APH.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Leadership

Alliance Pharma is a leading dividend payer. It pays a dividend yield of 3.75%, putting its dividend yield in the top 25% of dividend-paying stocks.

Dividend Growth

Alliance Pharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for APH.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: N/A

News Sentiment

Alliance Pharma has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Alliance Pharma this week, compared to 0 articles on an average week.

Search Interest

40 people have searched for APH on MarketBeat in the last 30 days. This is an increase of 48% compared to the previous 30 days.

MarketBeat Follows

1 people have added Alliance Pharma to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Alliance Pharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

11.95% of the stock of Alliance Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

66.34% of the stock of Alliance Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

APH Stock Analysis - Frequently Asked Questions

How have APH shares performed this year?

Alliance Pharma's stock was trading at GBX 45.55 at the start of the year. Since then, APH shares have increased by 33.5% and is now trading at GBX 60.80.
View the best growth stocks for 2025 here.

How do I buy shares of Alliance Pharma?

Shares of APH stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of Alliance Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Alliance Pharma investors own include boohoo group (BOO), BP (BP), Vodafone Group Public (VOD), Aviva (AV), Babcock International Group (BAB), BAE Systems (BA) and The Gym Group (GYM).

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: Electronic Equipment
• Current Symbol: LON:APH
• CUSIP: N/A
• CIK: N/A
• Web: www.alliancepharma.co.uk
• Phone: +44-1249-466966
• Fax: N/A
• Employees: 91,000
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: GBX 6,250
• High Stock Price Target: GBX 6,250
• Low Stock Price Target: GBX 6,250
• Potential Upside/Downside: +10,179.6%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): GBX (6.20)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 11.72
• P/E Growth: 1.04
• Net Income: £-33,646,875.10
• Net Margins: -18.34%
• Pretax Margin: N/A
• Return on Equity: -15.24%
• Return on Assets: 5.98%

Debt

• Debt-to-Equity Ratio: 46.27
• Current Ratio: 2.93
• Quick Ratio: 1.42

Sales & Book Value

• Annual Sales: £183.50 million
• Price / Sales: 1.79
• Cash Flow: GBX 7.73 per share
• Price / Cash Flow: 7.87
• Book Value: GBX 41.25 per share
• Price / Book: 1.47

Miscellaneous

• Outstanding Shares: 541,444,969
• Free Float: N/A
• Market Cap: £329.20 million
• Optionable: Not Optionable
• Beta: 0.67